Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine Nab-Paclitaxel

Next Previous
Trial Profile

Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine Nab-Paclitaxel

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vactosertib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 13 Jun 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Dec 2022.
  • 22 Jan 2022 According to trial design presented at the 2022 Gastrointestinal Cancers Symposium, as of September 2021, 5 patients have been enrolled in dose level (DL) 0 and 1 DLT has been reported in DL 0
  • 22 Jan 2022 Status changed from not yet recruiting to recruiting, according to trial design presented at the 2022 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top